Novo Nordisk Inc (NVO) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.

$99.95

Discover Novo Nordisk Inc’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.

Description

Using our intelligently designed and intuitive dataset, you can quickly understand how Novo Nordisk Inc (NVO) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Novo Nordisk Inc (NVO) lobbying for?

Summary of the lobbying data:
– Novo Nordisk Inc. hired several lobbying firms including Holland & Knight LLP and Public Strategies Washington to lobby on various general and specific issues related to taxation, pharmacy, health issues, law enforcement, Medicare/Medicaid, copyright, trademark and appropriations.
– They lobbied on specific bills such as H.R. 1577/S. 596 Treat and Reduce Obesity Act of 2021, H.R.1319 American Rescue Plan Act of 2021, and H.R.5376 Inflation Reduction Act.
– Novo Nordisk Inc. lobbied government agencies such as the White House Office, Department of Health & Human Services, Senate, and Centers for Medicare and Medicaid Services.

Inference about why Novo Nordisk Inc. is lobbying on these issues:
One could infer that Novo Nordisk Inc. is lobbying on the aforementioned issues to influence public policy in their favor and increase their profits. Their lobbying efforts related to obesity, diabetes prevention, and medication affordability may be geared toward expanding the market for their products. Furthermore, their lobbying on general issues related to copyright and patent protection may indicate an attempt to strengthen their intellectual property rights and prevent competition from generic drug manufacturers.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore